WSA
VRTX icon

Wealth Science Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Wealth Science Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.36M Buy
2,730
+694
+34% +$308K 0.6% 27
2026
Q1 		$923K Hold
2,036
– – 0.52% 24
2025
Q4 		$923K Buy
+2,036
New +$878K 0.53% 24

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Wealth Science Advisors's VRTX Position: Q2 2026 in Review

Wealth Science Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 34% in Q2 2026, buying an estimated $308K and bringing the position to 2,730 shares worth $1.36M. The position accounts for 0.6% of the portfolio, ranked #27.

Wealth Science Advisors first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. 1,014 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Wealth Science Advisors held 2,730 shares of Vertex Pharmaceuticals worth $1.36M as of Q2 2026.
  • Wealth Science Advisors bought 694 Vertex Pharmaceuticals shares in Q2 2026, an estimated $308K.
  • Vertex Pharmaceuticals made up 0.6% of Wealth Science Advisors's portfolio in Q2 2026, its #27 holding.
  • Wealth Science Advisors first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 1,014 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Wealth Science Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.